164 related articles for article (PubMed ID: 38069251)
1. The Role of KRAS Mutation in Colorectal Cancer-Associated Thrombosis.
Emilescu RA; Jinga M; Cotan HT; Popa AM; Orlov-Slavu CM; Olaru MC; Iaciu CI; Parosanu AI; Moscalu M; Nitipir C
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069251
[TBL] [Abstract][Full Text] [Related]
2. Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer.
Ades S; Kumar S; Alam M; Goodwin A; Weckstein D; Dugan M; Ashikaga T; Evans M; Verschraegen C; Holmes CE
J Thromb Haemost; 2015 Jun; 13(6):998-1003. PubMed ID: 25809746
[TBL] [Abstract][Full Text] [Related]
3. Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status.
Ortega Morán L; García Alfonso P; Aguilar Caballero I; Morón García B; Tirado Anula V; de Toro Carmena M; Soto Alsar J; Gutiérrez Alonso N; Bringas Beranek M; Martín Jiménez M; Muñoz Martín AJ
Clin Transl Oncol; 2020 Nov; 22(11):2026-2031. PubMed ID: 32270416
[TBL] [Abstract][Full Text] [Related]
4. Estimating Venous Thromboembolism Risk in Metastatic Colorectal Cancer Inpatients: Validation of Existing Risk Scores and Development of New Risk Scores.
Qin L; Liang Z; Xie J; Li X
Clin Appl Thromb Hemost; 2023; 29():10760296231196859. PubMed ID: 37691565
[TBL] [Abstract][Full Text] [Related]
5. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis.
Abufarhaneh M; Pandya RK; Alkhaja A; Iansavichene A; Welch S; Lazo-Langner A
Thromb Res; 2022 May; 213():47-56. PubMed ID: 35290837
[TBL] [Abstract][Full Text] [Related]
6. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes.
Saravani K; Salarzaei M; Parooie F
Hum Antibodies; 2021; 29(4):275-284. PubMed ID: 34334388
[TBL] [Abstract][Full Text] [Related]
7. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
10. Association between oncogenic status and risk of venous thromboembolism in patients with non-small cell lung cancer.
Dou F; Li H; Zhu M; Liang L; Zhang Y; Yi J; Zhang Y
Respir Res; 2018 May; 19(1):88. PubMed ID: 29743116
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
[TBL] [Abstract][Full Text] [Related]
12. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
[TBL] [Abstract][Full Text] [Related]
13. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
14. Tumor profiling of KRAS, BRAF, and NRAS gene mutations in patients with colorectal cancer: A Lebanese major center cohort study.
Baba O; Bidikian A; Mukherji D; Shamseddin A; Temraz S; Fakhruddin N; Khazzouh M; Ghizzawi D; Abdel Khalek R; Zaatari G; Mahfouz R
Gene; 2022 Aug; 834():146646. PubMed ID: 35680020
[TBL] [Abstract][Full Text] [Related]
15. Genes associated with venous thromboembolism in colorectal cancer patients.
Ünlü B; van Es N; Arindrarto W; Kiełbasa SM; Mei H; Westerga J; Middeldorp S; Kuppen PJK; Otten JMMB; Cannegieter S; Versteeg HH
J Thromb Haemost; 2018 Feb; 16(2):293-302. PubMed ID: 29247594
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer.
Morris VK; Lucas FAS; Overman MJ; Eng C; Morelli MP; Jiang ZQ; Luthra R; Meric-Bernstam F; Maru D; Scheet P; Kopetz S; Vilar E
Ann Oncol; 2014 Oct; 25(10):2008-2014. PubMed ID: 25009008
[TBL] [Abstract][Full Text] [Related]
18. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
Yarom N; Gresham G; Boame N; Jonker D
Clin Colorectal Cancer; 2019 Dec; 18(4):e309-e315. PubMed ID: 31547963
[TBL] [Abstract][Full Text] [Related]
19. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]